Technical Analysis for CORV - Correvio Pharma Corp

Grade Last Price % Change Price Change
grade F 2.4 -4.76% -0.120
CORV closed down 4.76 percent on Thursday, July 18, 2019, on 63 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CORV trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.76%
Inside Day Range Contraction -4.76%
Wide Bands Range Expansion -4.76%
Oversold Stochastic Weakness -4.76%
New 52 Week Closing Low Bearish -3.23%
Reversal New Lows Setup Bearish Swing Setup -3.23%

Older signals for CORV ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Correvio Pharma Corp is a Canada-based specialty pharmaceutical company. It provides brands that meet the needs of acute care physicians and patients. It develops, acquires and commercializes brands for the in-hospital, acute care market segment. The following is its portfolio of approved and marketed brands: Xydalba, for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP); Brinavess for the conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome, as well as Esmocard and Esmocard Lyo, a short-acting betablocker used to control rapid heart rate in a number of cardiovascular indications. Its pipeline of product candidates includes Trevyent, a drug device combination that is designed to deliver treprostinil.
Medicine Health RTT Pharmaceutical Infectious Diseases Acute Coronary Syndrome Tirofiban
Is CORV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.9
52 Week Low 2.4
Average Volume 9,420
200-Day Moving Average 3.9598
50-Day Moving Average 3.0588
20-Day Moving Average 2.821
10-Day Moving Average 2.687
Average True Range 0.1854
ADX 21.69
+DI 13.6115
-DI 29.2782
Chandelier Exit (Long, 3 ATRs ) 2.7038
Chandelier Exit (Short, 3 ATRs ) 2.9562
Upper Bollinger Band 3.2766
Lower Bollinger Band 2.3654
Percent B (%b) 0.04
BandWidth 32.300603
MACD Line -0.1639
MACD Signal Line -0.1264
MACD Histogram -0.0375
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.565
Resistance 3 (R3) 2.583 2.547 2.538
Resistance 2 (R2) 2.547 2.505 2.538 2.528
Resistance 1 (R1) 2.473 2.479 2.455 2.455 2.519
Pivot Point 2.437 2.437 2.428 2.428 2.437
Support 1 (S1) 2.363 2.395 2.345 2.345 2.281
Support 2 (S2) 2.327 2.369 2.318 2.272
Support 3 (S3) 2.253 2.327 2.263
Support 4 (S4) 2.235